A Phase 2 Study of AMG 337 in Subjects With Advanced or Metastatic Solid Tumors That Overexpress Mesenchymal Epithelial Transition (MET) Factor
Phase of Trial: Phase II
Latest Information Update: 05 Feb 2018
At a glance
- Drugs AMG 337 (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- Sponsors NantPharma
- 03 Jan 2018 Planned number of patients changed from 89 to 178.
- 03 Jan 2018 Status changed from not yet recruiting to recruiting.
- 12 May 2017 New trial record